';
CLOSE
Authors Posts by Cathy Barrick

Cathy Barrick

708 POSTS 0 COMMENTS

0 1967
NOTE TO INSPECTOR: The word "iridium" on the pen's nib is not a brand: it's the name of the metal of which the nib is made. Thanks. Inky old fountain pen on a $100 bill.

The Office of Developmental Programs (ODP) has shared ODPANN 24-086. This announcement provides the hourly wage and benefits ranges for specific participant directed services (PDS) provided to participants utilizing the Vendor Fiscal/Employer Agent (VF/EA) Financial Management Services (FMS) model, effective October 1, 2024. Please view the announcement for information and details.

0 1866

The Office of Developmental Programs (ODP) has shared ODPANN 24-085. The purpose of the announcement is to provide the hourly wage and benefits ranges for specific participant directed services (PDS) provided to participants utilizing the Agency With Choice (AWC) Financial Management Service (FMS) model effective October 1, 2024. Please view the announcement for details and information.

0 2791

The Office of Developmental Programs (ODP) has shared communication ODPANN 24-084, which informs stakeholders that rates for services rendered through ODP have been published as final in the Pennsylvania Bulletin.

There is a 30-day public comment period. Comments may be sent to the Department via email using subject header ”PN Fee Schedule.” Written comments can also be sent within 30 days to the Department of Human Services, Office of Developmental Programs, Division of Provider Assistance and Rate Setting, 4th Floor, Health and Welfare Building, 625 Forster Street, Harrisburg, PA 17120.

0 1094
Tablet on a desk - Newsletter

The Office of Developmental Programs (ODP) has released bulletin ODPANN 24-083. This communication is to announce the release of the latest issue of the CI Spotlight, which can be found on the Certified Investigator Program Home Page. This edition of the CI Program Spotlight includes articles on interviewing people who don’t communicate in universally understood ways, Temple University’s CI Peer Reviews, and more.

If you have a suggestion for a future Spotlight article, please visit here to submit your suggestion.

0 2069
Photo by Alena Shekhovtcova from Pexels

The FDA has approved and authorized for emergency use updated COVID-19 vaccines (2024-2025 formula) that include a monovalent (single) component that corresponds to the omicron variant KP.2 strain of SARS-CoV-2. These vaccines were updated to provide better protection against COVID-19 caused by circulating variants. Two vaccines are available for use in the United States: 2024–2025 Moderna COVID-19 Vaccine and 2024–2025 Pfizer-BioNTech COVID-19 Vaccine. There is no preference for one vaccine over the other when more than one vaccine is recommended for an age group

Who should get the vaccine?

Everyone ages 6 months and older should get the 2024–2025 COVID-19 vaccine. This includes people who have received a COVID-19 vaccine before and people who have had COVID-19. The COVID-19 vaccine helps protect you from severe disease, hospitalization, and death.

It is especially important to get your 2024–2025 COVID-19 vaccine if you are:

  • Ages 65 and older,
  • At high risk for severe COVID-19
  • Have never received a COVID-19 vaccine.
  • Are living in a long-term care facility
  • Are pregnant, breastfeeding, trying to get pregnant, or might become pregnant in the future.
  • Want to lower your risk of getting Long COVID

People who recently had COVID-19:

  • People who recently had COVID-19 may delay getting a COVID-19 vaccine for 3 months.
  • The risk of getting COVID-19 is less likely in the weeks to months following a SARS-CoV-2 infection.

Certain factors could be reasons to get a vaccine sooner rather than later, such as:

  • Personal risk of severe COVID-19
  • Risk of COVID-19 in a family or household member or other close contact
  • local levels of COVID-19 illness

Keep in mind‎:

  • Vaccine protection decreases over time, so it is important to stay up to date with your COVID-19 vaccine.
  • Getting a COVID-19 vaccine is a safer, more reliable way to build protection than getting sick with COVID-19.

0 1262

ANCOR is working in partnership with the State of the States in Intellectual and Developmental Disabilities Project of National Significance at the University of Kansas to evaluate promising practices and strategies to enhance technology use by people with I/DD across the US and the landscape of access resulting from flexibilities provided during the COVID-19 pandemic.

It is essential that ANCOR drives a high response rate to ensure they capture a full picture of what providers are doing and experiencing in the field. Please help them not only get the word out, but also encourage your members to participate! Take the survey here.

But wait! There’s more… ANCOR will also be offering a sneak peek at the results during their upcoming Tech Summit on October 29! After that, the full report will be released by the University of Kansas, which they will share, as well.

0 1345

The Quality Management (QM) Data Collection Tool for CPS and Day Habilitation now has a short tutorial video available on the CPS resource page on the MyODP website. You can view it here.

In addition, an unprotected version of the tool is available due to multiple requests. Please be aware that using the unprotected version could inadvertently change the formulas when editing other cells, meaning the formulas could display incorrect calculations or an error.

Prev1...495051...71Next Page 50 of 71
© 2021 - Rehabilitation & Community Providers Association